世界最新医学信息文摘（连续型电子期刊）
世界最新醫學信息文摘（連續型電子期刊）
세계최신의학신식문적（련속형전자기간）
World Latest Medicine Information
2014年
35期
187-188
,共2页
卡哈尔江·阿不都外力%段惠洁%刘春玲
卡哈爾江·阿不都外力%段惠潔%劉春玲
잡합이강·아불도외력%단혜길%류춘령
重组人血管内皮抑制素%恩度%非小细胞肺癌%联合治疗%疗效
重組人血管內皮抑製素%恩度%非小細胞肺癌%聯閤治療%療效
중조인혈관내피억제소%은도%비소세포폐암%연합치료%료효
endostar%non-small cell lung cancer%comprehensive chemotherapy
目的：观察重组人血管内皮抑素(恩度)联合含铂类化疗方案治疗晚期非小细胞肺癌患者的近期临床疗效、不良反应。方法收集Ⅲ、Ⅳ期非小细胞肺癌患者54例，给予dP、nP、GP方案化疗同时联合给予恩度15mg，连用2周后暂停1周为1周期，至少完成2个周期。治疗前后对目标病灶进行ct检查及病灶测量，参照WHo标准评价近期客观疗效；化疗期间每周查血常规及心电图1次，化疗后查血常规、肝肾功能、心电图，并观察记录治疗引起的毒副反应。结果54例患者中部分缓解22例(40.74％)，稳定20例(37.03％)，进展12例(22.23％)，有效率为40.74％，临床受益率为77.78％；不良反应主要为骨髓抑制和消化道毒性，发生Ⅲ～Ⅳ度贫血5例(9.25％)，Ⅲ～Ⅳ度呕吐6例(11.12％)，发生st—t改变8例(14.81％)，患者经对症处理后可耐受。结论恩度联合含铂类化疗方案治疗晚期nsclc的近期客观疗效较高，安全性好，但远期疗效仍需观察。
目的：觀察重組人血管內皮抑素(恩度)聯閤含鉑類化療方案治療晚期非小細胞肺癌患者的近期臨床療效、不良反應。方法收集Ⅲ、Ⅳ期非小細胞肺癌患者54例，給予dP、nP、GP方案化療同時聯閤給予恩度15mg，連用2週後暫停1週為1週期，至少完成2箇週期。治療前後對目標病竈進行ct檢查及病竈測量，參照WHo標準評價近期客觀療效；化療期間每週查血常規及心電圖1次，化療後查血常規、肝腎功能、心電圖，併觀察記錄治療引起的毒副反應。結果54例患者中部分緩解22例(40.74％)，穩定20例(37.03％)，進展12例(22.23％)，有效率為40.74％，臨床受益率為77.78％；不良反應主要為骨髓抑製和消化道毒性，髮生Ⅲ～Ⅳ度貧血5例(9.25％)，Ⅲ～Ⅳ度嘔吐6例(11.12％)，髮生st—t改變8例(14.81％)，患者經對癥處理後可耐受。結論恩度聯閤含鉑類化療方案治療晚期nsclc的近期客觀療效較高，安全性好，但遠期療效仍需觀察。
목적：관찰중조인혈관내피억소(은도)연합함박류화료방안치료만기비소세포폐암환자적근기림상료효、불량반응。방법수집Ⅲ、Ⅳ기비소세포폐암환자54례，급여dP、nP、GP방안화료동시연합급여은도15mg，련용2주후잠정1주위1주기，지소완성2개주기。치료전후대목표병조진행ct검사급병조측량，삼조WHo표준평개근기객관료효；화료기간매주사혈상규급심전도1차，화료후사혈상규、간신공능、심전도，병관찰기록치료인기적독부반응。결과54례환자중부분완해22례(40.74％)，은정20례(37.03％)，진전12례(22.23％)，유효솔위40.74％，림상수익솔위77.78％；불량반응주요위골수억제화소화도독성，발생Ⅲ～Ⅳ도빈혈5례(9.25％)，Ⅲ～Ⅳ도구토6례(11.12％)，발생st—t개변8례(14.81％)，환자경대증처리후가내수。결론은도연합함박류화료방안치료만기nsclc적근기객관료효교고，안전성호，단원기료효잉수관찰。
Objective to observe the efficacy and adverse reactions of endostatin injection(endostar) combined with platinum-based regimen in patients with advanced non-small cell lung cancer(nsclc).Methods collecting 54 cases of stageⅢ , Ⅳ non-small cell lung cancer, administrated with endostar plus dP、nP、GP. regimen,endostar 15mg day 1 to 14, repeated 3weeks.all patients should completed 2 cycles at least.it was need ct examination before and after treatment to measure the target lesion.the near-term objective response was appraised by the standard of WHo.checking blood routine test and electrocardiogram during chemotherapy 1 times a week,check liver and kidney function, electrocardiogram, blood tests after hemotherapy,and observe and record the toxic side effects.Results among 54 cases,there were 22 cases Pr(40.74%),20cases sd(37.03 % )and 6 cases Pd(22.23 % ).overall response rate was 40.74 % ,the clinical beneift rate was 77.78 % ,the main toxicities were leucopenia and nausea vomiting.the G1-G4 toxicities including anemia 5 caces(9.25 % ),vomiting 6cases(11.12%),these were 8 cases occurred st-t change(14.81%).all patients can be tolerated after symptomatic treatment. Conclusion endostar combined chemotherapy were effective and safe in treatment of advanced NSCLC.But the long-term efifcacy still needs further observation.
